Interactive visualization of Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) — a key immune receptor implicated in Alzheimer's disease.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is an immunoglobulin-like receptor expressed on microglia in the brain. Variants in TREM2, particularly R47H, are associated with significantly increased risk of Alzheimer's disease.
Key Functions:
Disease Relevance: Loss-of-function TREM2 variants impair microglial response to amyloid plaques, reduce phagocytic activity, and alter inflammatory signaling — contributing to neurodegeneration.
Structure Information: This structure (PDB: 5UD7) shows the wild-type immunoglobulin-like domain of human TREM2. The structure reveals the molecular basis for how disease-associated variants like R47H disrupt ligand binding.
Citation: Sudom A, et al. (2018) Molecular basis for the loss-of-function effects of the Alzheimer's disease-associated R47H variant of the immune receptor TREM2. J Biol Chem 293(33):12634-12646. PMID: 29794134
TREM2 features prominently in several SciDEX debates and hypotheses: